<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">porozendo</journal-id><journal-title-group><journal-title xml:lang="ru">Остеопороз и остеопатии</journal-title><trans-title-group xml:lang="en"><trans-title>Osteoporosis and Bone Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-2680</issn><issn pub-type="epub">2311-0716</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/osteo2013219-21</article-id><article-id custom-type="elpub" pub-id-type="custom">porozendo-8854</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>ОСТЕОНЕКРОЗ ЧЕЛЮСТЕЙ КАК ОСЛОЖНЕНИЕ ТЕРАПИИ БИСФОСФОНАТАМИ В СТОМАТОЛОГИЧЕСКОЙПРАКТИКЕ</article-title><trans-title-group xml:lang="en"><trans-title>OSTEONEKROZ ChELYuSTEY KAK OSLOZhNENIE TERAPII BISFOSFONATAMI V STOMATOLOGIChESKOYPRAKTIKE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>БУЙКО</surname><given-names>М А</given-names></name><name name-style="western" xml:lang="en"><surname>BUYKO</surname><given-names>M A</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант Кафедры терапевтической стоматологии ФПДО</p></bio><bio xml:lang="en"/><email xlink:type="simple">mashabuyko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>АТРУШКЕВИЧ</surname><given-names>В Г</given-names></name><name name-style="western" xml:lang="en"><surname>ATRUShKEVICh</surname><given-names>V G</given-names></name></name-alternatives><bio xml:lang="ru"><p>профессор Кафедры терапевтической стоматологии ФПДО</p></bio><bio xml:lang="en"/><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Московский Государственный Медико-Стоматологический Университет им. А.И. Евдокимова</aff><aff xml:lang="en"></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2013</year></pub-date><volume>16</volume><issue>2</issue><issue-title>№2 (2013)</issue-title><fpage>19</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; БУЙКО М.А., АТРУШКЕВИЧ В.Г., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">БУЙКО М.А., АТРУШКЕВИЧ В.Г.</copyright-holder><copyright-holder xml:lang="en">BUYKO M.A., ATRUShKEVICh V.G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.osteo-endojournals.ru/jour/article/view/8854">https://www.osteo-endojournals.ru/jour/article/view/8854</self-uri><abstract/><trans-abstract xml:lang="en"/></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по остеопорозу (под редакцией Беневоленской Л.И.) Бином, Москва, 2010, 196—216.</mixed-citation><mixed-citation xml:lang="en">Руководство по остеопорозу (под редакцией Беневоленской Л.И.) Бином, Москва, 2010, 196—216.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled, clinical trials. J Clin Oncology 19:558, 2001.</mixed-citation><mixed-citation xml:lang="en">Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled, clinical trials. J Clin Oncology 19:558, 2001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hillner BE, Ingle JN, Chelbowski RT, et.al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042, 2003.</mixed-citation><mixed-citation xml:lang="en">Hillner BE, Ingle JN, Chelbowski RT, et.al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042, 2003.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458, 200.2</mixed-citation><mixed-citation xml:lang="en">Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458, 200.2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16; 144(10):753—61. Erratum in: Ann Intern Med. 2006 Aug 1;145(3):235.</mixed-citation><mixed-citation xml:lang="en">Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16; 144(10):753—61. Erratum in: Ann Intern Med. 2006 Aug 1;145(3):235.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 65:369, 2007.</mixed-citation><mixed-citation xml:lang="en">American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 65:369, 2007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecro-sis of the auditory canal. Br J Haematol. 2006 Jan; 132(1):114.</mixed-citation><mixed-citation xml:lang="en">Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecro-sis of the auditory canal. Br J Haematol. 2006 Jan; 132(1):114.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards BJ, Gounder M, McKoy JM et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008; 9(12):1166—72.</mixed-citation><mixed-citation xml:lang="en">Edwards BJ, Gounder M, McKoy JM et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008; 9(12):1166—72.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hohnecker JA. Novartis «Dear Doctor» Precautions added to label of Aredia and Zometa. September 24, 2004.</mixed-citation><mixed-citation xml:lang="en">Hohnecker JA. Novartis «Dear Doctor» Precautions added to label of Aredia and Zometa. September 24, 2004.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115—7.</mixed-citation><mixed-citation xml:lang="en">Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115—7.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res.2007;22(10):1479—91.</mixed-citation><mixed-citation xml:lang="en">Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res.2007;22(10):1479—91.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Coxon FP. An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity. Bone. 2008,2, 203—207.</mixed-citation><mixed-citation xml:lang="en">Coxon FP. An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity. Bone. 2008,2, 203—207.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Allen R, Ruggiero S L. Osteonecrosis of the Jaw : Recent Clinical and Preclinical Advances. Bone.2011, 3,189—196.</mixed-citation><mixed-citation xml:lang="en">Allen R, Ruggiero S L. Osteonecrosis of the Jaw : Recent Clinical and Preclinical Advances. Bone.2011, 3,189—196.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Somerman J., McCauley L K. Bisphosphonates — Sacrifing the Jaw to Save the Skeleton? Martha J.Somerman, Bone.2006, 5, 378—397.</mixed-citation><mixed-citation xml:lang="en">Somerman J., McCauley L K. Bisphosphonates — Sacrifing the Jaw to Save the Skeleton? Martha J.Somerman, Bone.2006, 5, 378—397.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med 353:100, 2005.</mixed-citation><mixed-citation xml:lang="en">Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med 353:100, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone. 2011 Oct; 49(4):710—6.</mixed-citation><mixed-citation xml:lang="en">Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone. 2011 Oct; 49(4):710—6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Marth J.Somerman, Laurie K.McCauley.Bisphosphonates — Sacrificing the Jaw to Save the Skeleton. Bone. 2010, 12, 109—112.</mixed-citation><mixed-citation xml:lang="en">Marth J.Somerman, Laurie K.McCauley.Bisphosphonates — Sacrificing the Jaw to Save the Skeleton. Bone. 2010, 12, 109—112.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jontell M, Landesberg R, Laslop A. Osteonecrosis of the Jaw and bisphosphonate treatment for osteoporosis.Bone. 2007,4,46—53.</mixed-citation><mixed-citation xml:lang="en">Jontell M, Landesberg R, Laslop A. Osteonecrosis of the Jaw and bisphosphonate treatment for osteoporosis.Bone. 2007,4,46—53.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Boyde A.Jaw Bone Necrosis and Bisphosphonates : Micro-anatomical Questions. Bone.2006, 4, 158-162.Bone. 3, 141—153.</mixed-citation><mixed-citation xml:lang="en">Boyde A.Jaw Bone Necrosis and Bisphosphonates : Micro-anatomical Questions. Bone.2006, 4, 158-162.Bone. 3, 141—153.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Робустова Т.Г. Хирургическая стоматология.1996, 134—138.</mixed-citation><mixed-citation xml:lang="en">Робустова Т.Г. Хирургическая стоматология.1996, 134—138.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Capsoni F, Longhi M. Bisphosphonate — associated osteonecrosis of the jaw: the rheumatologists role. Arthritis Research &amp; Therapy. 2006, 8, 219</mixed-citation><mixed-citation xml:lang="en">Capsoni F, Longhi M. Bisphosphonate — associated osteonecrosis of the jaw: the rheumatologists role. Arthritis Research &amp; Therapy. 2006, 8, 219</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Allen M R, Burr D B. Mineralization, Microdamage, and Matrix: How Bisphosphonates Influence Material Properties of Bone. Bone.2007, 4(2), 49—60.</mixed-citation><mixed-citation xml:lang="en">Allen M R, Burr D B. Mineralization, Microdamage, and Matrix: How Bisphosphonates Influence Material Properties of Bone. Bone.2007, 4(2), 49—60.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Perez S B, Barrero M V. Bisphosphonate — associated osteonecrosis of the jaw.MedOralPatolBucal. 2008,13 (12), 770.</mixed-citation><mixed-citation xml:lang="en">Perez S B, Barrero M V. Bisphosphonate — associated osteonecrosis of the jaw.MedOralPatolBucal. 2008,13 (12), 770.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Reid I.R. Pathogenesis of Osteonecrosis of the Jaw. Bone. 2009, 11, 178-186.</mixed-citation><mixed-citation xml:lang="en">Reid I.R. Pathogenesis of Osteonecrosis of the Jaw. Bone. 2009, 11, 178-186.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Otto S, Paulke C.Osteonecrosis of the Jaw, Bone.2009,4, 63-70.</mixed-citation><mixed-citation xml:lang="en">Otto S, Paulke C.Osteonecrosis of the Jaw, Bone.2009,4, 63-70.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Said F, Ghoul-Mazgar S, Khemiss F, El Ayeb H, Saidane D, Berdal A. The effect bisphosphonates on the periodontium of ovari-oectomized rats.J Periodontol. 2012 Aug;83(8):1063—8.</mixed-citation><mixed-citation xml:lang="en">Said F, Ghoul-Mazgar S, Khemiss F, El Ayeb H, Saidane D, Berdal A. The effect bisphosphonates on the periodontium of ovari-oectomized rats.J Periodontol. 2012 Aug;83(8):1063—8.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
